tiprankstipranks
Atara Biotherapeutics (GB:0HIY)
LSE:0HIY
UK Market

Atara Biotherapeutics Stock Analysis & Ratings

GB:0HIY Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.00 - $0.00
Previous Close$5.58
VolumeN/A
Average Volume (3M)187.00
Market Cap$520.74M
P/E RatioN/A
Beta2.22
Next EarningsAug 08, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score5
EPS (TTM)0.00


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

GB:0HIY FAQ

What was Atara Biotherapeutics’s price range in the past 12 months?
Atara Biotherapeutics lowest stock price was $0.00 and its highest was $0.00 in the past 12 months.
    What is Atara Biotherapeutics’s market cap?
    Atara Biotherapeutics’s market cap is $520.74M.
      What is Atara Biotherapeutics’s price target?
      The average price target for Atara Biotherapeutics is $30.83. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $67.00 ,the lowest forecast is $8.00. The average price target represents 453.00% Increase from the current price of $5.575.
        What do analysts say about Atara Biotherapeutics?
        Atara Biotherapeutics’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.
          When is Atara Biotherapeutics’s upcoming earnings report date?
          Atara Biotherapeutics’s upcoming earnings report date is Aug 08, 2022 which is in 82 days.
            How were Atara Biotherapeutics’s earnings last quarter?
            Atara Biotherapeutics released its earnings results on May 05, 2022. The company reported -$0.87 earnings per share for the quarter, beating the consensus estimate of -$0.932 by $0.062.
              Is Atara Biotherapeutics overvalued?
              According to Wall Street analysts Atara Biotherapeutics’s price is currently Undervalued.
                Does Atara Biotherapeutics pay dividends?
                Atara Biotherapeutics does not currently pay dividends.
                What is Atara Biotherapeutics’s EPS estimate?
                Atara Biotherapeutics’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Atara Biotherapeutics have?
                Atara Biotherapeutics has 93,410,000 shares outstanding.
                  What happened to Atara Biotherapeutics’s price movement after its last earnings report?
                  Atara Biotherapeutics reported an EPS of -$0.87 in its last earnings report, beating expectations of -$0.932. Following the earnings report the stock price went same 0%.
                    Which hedge fund is a major shareholder of Atara Biotherapeutics?
                    Among the largest hedge funds holding Atara Biotherapeutics’s share is Baupost Group LLC. It holds Atara Biotherapeutics’s shares valued at 75M.

                      ---

                      Atara Biotherapeutics Stock Analysis

                      The Atara Biotherapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Atara Biotherapeutics

                      Atara Biotherapeutics, Inc. operates as a clinical stage company, which engages in the development of novel therapeutics for patients with cancer, autoimmune, and viral diseases. Its pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in South San Francisco, CA.

                      ---
                      Similar Stocks
                      Company
                      Price & Change
                      Follow
                      Amgen
                      AVEO Pharma
                      Karyopharm Therapeutics
                      Actinium Pharmaceuticals
                      Brickell Biotech

                      Popular Stocks

                      ---
                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis